# Jeffrey A. Engelman

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jeffrey-a-engelman/

## Facts

| Field | Value |
| --- | --- |
| Citations | 86,315 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 132 |
| i10-index | 227 |
| Last Known Institution | Cancer Research Center |
| OpenAlex ID | https://openalex.org/A5040093136 |
| ORCID iD | 0009-0004-0775-4523 |
| Works | 876 |

## Researcher papers

Showing 12 of 35.

- [Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/anaplastic-lymphoma-kinase-inhibition-in-non-small-cell-lung-cancer/)
- [<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling](https://scholariq.org/papers/i-met-i-amplification-leads-to-gefitinib-resistance-in-lung-cancer-by-activating/)
- [Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors](https://scholariq.org/papers/genotypic-and-histological-evolution-of-lung-cancers-acquiring-resistance-to/)
- [The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism](https://scholariq.org/papers/the-evolution-of-phosphatidylinositol-3-kinases-as-regulators-of-growth-and/)
- [Systematic identification of genomic markers of drug sensitivity in cancer cells](https://scholariq.org/papers/systematic-identification-of-genomic-markers-of-drug-sensitivity-in-cancer-cells/)
- [Targeting PI3K signalling in cancer: opportunities, challenges and limitations](https://scholariq.org/papers/targeting-pi3k-signalling-in-cancer-opportunities-challenges-and-limitations/)
- [Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway](https://scholariq.org/papers/dependency-of-a-therapy-resistant-state-of-cancer-cells-on-a-lipid-peroxidase/)
- [Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints](https://scholariq.org/papers/adaptive-resistance-to-therapeutic-pd-1-blockade-is-associated-with-upregulation/)
- [<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers](https://scholariq.org/papers/i-ros1-i-rearrangements-define-a-unique-molecular-class-of-lung-cancers/)
- [Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/ceritinib-in-i-alk-i-rearranged-non-small-cell-lung-cancer/)
- [Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers](https://scholariq.org/papers/mechanisms-of-acquired-crizotinib-resistance-in-alk-rearranged-lung-cancers/)
- [Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study](https://scholariq.org/papers/activity-and-safety-of-crizotinib-in-patients-with-alk-positive-non-small-cell/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Cancer Research Center](https://scholariq.org/institutions/cancer-research-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.